Wan‐Long Chuang
YOU?
Author Swipe
View article: Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure
Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure Open
Hepatitis C virus (HCV) infection is an infectious disease carrying a high risk of metabolic disorders. Chronic HCV (CHC) patients can possess extrahepatic manifestations such as diabetes, steatotic liver disease (SLD), and other metabolic…
View article: HCV elimination in hyperendemic areas: Experiences in Taiwan
HCV elimination in hyperendemic areas: Experiences in Taiwan Open
Hepatitis C virus (HCV) remains a major global health burden, particularly in regions with limited access to healthcare. In 2017, Taiwan launched its National Hepatitis C Elimination Program, aiming for national elimination by 2025 through…
View article: Phase <scp>IIb</scp> Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine
Phase <span>IIb</span> Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine Open
This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intra…
View article: The Proteomic Profiling of Circulating Extracellular Vesicles of Western Diet and Chemical‐Induced Murine <scp>MASH</scp> Model
The Proteomic Profiling of Circulating Extracellular Vesicles of Western Diet and Chemical‐Induced Murine <span>MASH</span> Model Open
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver condition that can progress to severe complications such as metabolic dysfunction‐associated steatohepatitis (MASH). Despite its gr…
View article: Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment Open
Background Tenofovir alafenamide (TAF) has shown non‐inferior efficacy to tenofovir disoproxil fumarate (TDF), with superior bone and renal safety. Aim To characterise 5‐year TAF efficacy and safety in patients of East Asian ethnicity from…
View article: Hepatitis C virus and cardiovascular disease: Current knowledge and unmet needs
Hepatitis C virus and cardiovascular disease: Current knowledge and unmet needs Open
A BSTRACT The relationship between hepatitis C virus (HCV) infection and cardiovascular disease (CVD) is increasingly recognized, with studies indicating elevated CVD prevalence and mortality among individuals with HCV. Chronic HCV patient…
View article: Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study Open
Previous studies with JNJ-73763989 (JNJ-3989) ± bersacapavir (JNJ-56136379) and nucleos(t)ide analogs (NAs) in patients with chronic hepatitis B (CHB) have demonstrated JNJ-3989 dose-dependent and robust reductions in viral markers; howeve…
View article: Dynamics of Cardiometabolic Risk Factors Are Linked to the Risk of Hypertension and Diabetes in MASLD
Dynamics of Cardiometabolic Risk Factors Are Linked to the Risk of Hypertension and Diabetes in MASLD Open
This study investigates the impact of cardiometabolic risk factors (CMRF) on the prevalence and incidence of hypertension (HTN) and diabetes mellitus (DM) in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD)…
View article: Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from Taiwan
Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from Taiwan Open
NCT03180619/GS-US-320-4035.
View article: Association of CD33 genetic variants with neurocognitive profiles in chronic viral hepatitis
Association of CD33 genetic variants with neurocognitive profiles in chronic viral hepatitis Open
Background CD33 has been implicated in the pathogenesis of Alzheimer’s disease primarily through its role in inhibiting the clearance of beta-amyloid (Aβ). However, genetic studies yield mixed results and it is unclear whether the impact o…
View article: Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan Open
This study examines the impact of hepatitis C virus (HCV) eradication through sofosbuvir/velpatasvir (SOF/VEL) treatment on glycated hemoglobin (HbA1c) levels in patients with chronic hepatitis C and type 2 diabetes mellitus (T2DM). Utiliz…
View article: A Point‐of‐Care Model for Hepatitis C Elimination in Remote Islands of Taiwan
A Point‐of‐Care Model for Hepatitis C Elimination in Remote Islands of Taiwan Open
Timely and efficient diagnosis of hepatitis C virus (HCV) infection remains the effective approach for the subsequent care cascade of HCV treatment. It is of importance in under‐resourced areas. The study aimed to assess the feasibility of…
View article: Design of a Novel Transition-Based Deadlock Recovery Policy for Flexible Manufacturing Systems
Design of a Novel Transition-Based Deadlock Recovery Policy for Flexible Manufacturing Systems Open
In the domain of application of PN theory, the system deadlock problem of a flexible manufacturing system (FMS) is a thorny problem that needs to be solved urgently. All the research has the same objective of designing optimal controllers …
View article: Circulating let‐7 Predicts Hepatic Fibrogenesis of 12‐Month Post‐Nucleos(t)ide Analog Treatment in Patients With Hepatitis B Virus
Circulating let‐7 Predicts Hepatic Fibrogenesis of 12‐Month Post‐Nucleos(t)ide Analog Treatment in Patients With Hepatitis B Virus Open
Chronic hepatitis B virus (HBV) infection is associated with potential complications of liver cirrhosis and hepatocellular carcinoma. To date, there are no effective and noninvasive clinical markers that can predict the risk of liver fibro…
View article: Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues Open
Background/Aims: Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.Methods: We analyzed dat…
View article: Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes Open
BACKGROUND Insulin resistance, lipotoxicity, and mitochondrial dysfunction contribute to the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). Mitochondrial dysfunction impairs oxidative phosphorylation and …
View article: Design of Maximally Permissive Controllers for Solving Deadlock Problems in Flexible Manufacturing Systems
Design of Maximally Permissive Controllers for Solving Deadlock Problems in Flexible Manufacturing Systems Open
Industry 5.0 aims to integrate humans and machines to achieve greater productivity, personalization, and sustainable development in the production process. Built on the foundation of Industry 4.0 which emphasizes automation, digitalization…
View article: Air pollution causes abnormal alanine aminotransferase levels in patients with chronic hepatitis B
Air pollution causes abnormal alanine aminotransferase levels in patients with chronic hepatitis B Open
Background: To investigate the association between air pollution and abnormal alanine aminotransferase levels in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs. Methods: This cross-sectional study enrolled 1,2…
View article: Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study Open
Background/Aims: The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C, remains …
View article: High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C Open
Patients with CHC with high-normal and abnormal posttreatment ALT levels have an increased risk of HCC; thus, HCC surveillance is still necessary in this population.
View article: Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program Open
Posttreatment FIB-4 score and its change from baseline can be used to stratify HCC risk in patients with CHC receiving DAAs.
View article: Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis <scp>C virus</scp> registry in Taiwan
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis <span>C virus</span> registry in Taiwan Open
An 8‐week regimen of glecaprevir/pibrentasvir is recommended for treatment‐naïve patients with chronic hepatitis C (CHC). In alignment with the Taiwanese government's objective to eliminate hepatitis C by 2025, this study aimed to provide …
View article: Hepatitis C virus‐free endoscope procedures project: An in‐hospital elimination approach
Hepatitis C virus‐free endoscope procedures project: An in‐hospital elimination approach Open
Hepatitis C virus (HCV) elimination in the care cascades for patients receiving invasive procedures remains elusive. This study aimed to evaluate the efficacy of HCV‐free Endoscope Procedures Project (CEPP) in the effort toward hospital HC…
View article: Safety of transarterial chemoembolization on renal function in combined hepatocellular carcinoma and chronic kidney disease patients
Safety of transarterial chemoembolization on renal function in combined hepatocellular carcinoma and chronic kidney disease patients Open
This study was to investigate the safety of transarterial chemoembolization (TACE) which required injection of contrast medium on renal function in combined hepatocellular carcinoma and chronic kidney disease (CKD) patients. A total of 265…